Circa Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Receives FDA approval for its 4 mg polacrilex nicotine gum (ANDA 74-707) March 19. The Watson Pharmaceutical subsidiary also receives approval for a 2 mg version of the product (ANDA 74-507) March 15. SmithKline Beecham's Nicorette smoking cessation gum, the reference product, lost its Waxman/Hatch exclusivity Feb. 9, but launched a mint-flavored gum in January to stave off the private label competition ("The Tan Sheet" Jan. 18, p. 4). The Circa product is the first private label nicotine gum to be approved by the agency. Novopharm, Gumtech and Perrigo also are expected to market nicotine replacement gum in the future
You may also be interested in...
SmithKline Seeks Injunction Against Watson Nicotine Gum Labeling
SmithKline Beecham Consumer Healthcare alleges copyright infringement of the company's Nicorette smoking cessation gum in a lawsuit filed against Watson Pharmaceuticals and its subsidiaries, Watson Laboratories and Circa Pharmaceuticals, Aug. 26.
SmithKline Seeks Injunction Against Watson Nicotine Gum Labeling
SmithKline Beecham Consumer Healthcare alleges copyright infringement of the company's Nicorette smoking cessation gum in a lawsuit filed against Watson Pharmaceuticals and its subsidiaries, Watson Laboratories and Circa Pharmaceuticals, Aug. 26.
SmithKline Seeks Injunction Against Watson Nicotine Gum Labeling
SmithKline Beecham Consumer Healthcare alleges copyright infringement of the company's Nicorette smoking cessation gum in a lawsuit filed against Watson Pharmaceuticals and its subsidiaries, Watson Laboratories and Circa Pharmaceuticals, Aug. 26.